COOL Prime: Comparative Effectiveness for Cooling mild HIE PCORI PCORI PIR-1552Nov 1, 2022 - Oct 31, 2027 Role: Site-PI Description: This is a comparative effectiveness evaluation of cooling for mild HIE (Hypoxic-ischemic encephalopathy) within a prospective cohort of infants at 14 academic centers whose practices are mixed for either therapeutic hypothermia or supportive care. The central aim is to determine if there are differences in the primary outcome of Bayley 4 exams at 2 years, Child Behavior Checklist and Hammersmith Neonatal and Infant Neurological Exams, in infants meeting predefined criteria for mild HIE based on the use of cooling or supportive care. Furthermore, this study aims to determine and infant safety composite outcome to determine the risk of therapeutic hypothermia versus normothermia in this population and the effect on mother-infant measures or stress, bonding and breastfeeding at 3-4 months of age. |
Endothelial tip cell-mediated angiogenesis and repair after neonatal stroke NIH/NINDS 2R01NS107039Sep 22, 2022 - Aug 31, 2027 Role: PI Description: To determine role of EPO in modulating angiogenesis and fibrosis as a delayed treatment strategy for neonatal stroke. |
The Child Health Research Career Development Program at UCSF NIH/NICHD K12HD105250Apr 1, 2021 - Mar 31, 2026 Role: Co-I, Recruitment Director Description: This program is an investment in the future of children’s health, as the diverse group of researchers we will train will harness advanced research strategies to address urgent problems (e.g., asthma, cancer, infectious diseases, host defense defects, diabetes, obesity and developmental malformations of the heart, brain and other organs), resulting in new treatments to improve child health outcomes. |
Quantifying Metabolic Changes in the Newborn Brain Following Stroke NIH/NCATS RAS A127522Jun 1, 2018 - May 31, 2019 Role: PI |
Enhanced cellular therapy for neonatal stroke NIH R01NS107039Dec 15, 2017 - Nov 30, 2021 Role: Principal Investigator Description: The goal of this project is to determine the mechanisms of regeneration and repair with delayed cellular therapy for neonatal stroke by focusing on the vascular response to brain injury. This will study the effects of mesenchymal stem cells pre-treated with erythropoietin on long-term outcomes. |
Cerebral focal ischemia-reperfusion injury Anida Pharma, Inc. AnidaMar 1, 2017 - Feb 28, 2018 Role: Co-investigator |
Precision Therapy for Neonatal Brain Injury NIH R35NS097299Dec 1, 2016 - Nov 30, 2024 Role: Co-Investigator |
High-dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) CCC NIH U01NS092764Sep 30, 2016 - Jun 30, 2021 Role: Site-PI, Executive Committee Member |
The Role of Erythropoietin in Enhancing Synaptic Plasticity and Neural Circuit Formation after Neonatal Stroke UCSF REACJan 1, 2015 - Jun 30, 2016 Role: PI |
Repair after Neonatal Brain Injury NIH P01NS082330Jan 1, 2014 - Dec 31, 2020 Role: Co-Investigator |
Harrington DiscoveryJan 1, 2014 - Dec 31, 2015 Role: Co-Investigator |
Effects of neonatal stroke and erythropoietin on cell fate and neurogenesis UCSF RAPJan 1, 2012 - Dec 31, 2014 Role: PI |
Erythropoietin and Neurogenesis after Neonatal Stroke NIH K08NS064094Mar 1, 2011 - Feb 29, 2016 Role: Principal Investigator |
Mechanisms of Ischemic Neonatal Brain Injury NIH P50NS035902Apr 1, 1997 - Jan 31, 2015 Role: Co-Investigator |